We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+13.93%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$494M
AUM Growth
+$45M
Cap. Flow
+$16.8M
Cap. Flow %
3.4%
Top 10 Hldgs %
73.47%
Holding
50
New
5
Increased
15
Reduced
12
Closed
9
Avg Time Held
7.5 quarters
Top 10 Avg Time Held
8.2 quarters
Top 20 Avg Time Held
6.3 quarters

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$21.3M
2
CDXS icon
Codexis
CDXS
+$7.27M
3
LRMR icon
Larimar Therapeutics
LRMR
+$5.08M
4
IRON icon
Disc Medicine
IRON
+$4.76M
5
VIGL icon
Vigil Neuroscience
VIGL
+$4.48M

Top Sells

Rank Stock Value
1
DNA icon
Ginkgo Bioworks
DNA
+$5.38M
2
PVLA icon
Palvella Therapeutics
PVLA
+$4.82M
3
ANAB icon
AnaptysBio
ANAB
+$4.66M
4
SLRN icon
ACELYRIN
SLRN
+$3.99M
5
TARA icon
Protara Therapeutics
TARA
+$3.02M

Sector Composition

Rank Sector Weight
1 Healthcare 97.87%
2 Miscellaneous 2.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HROW icon
1
Harrow
HROW
$1.09B
$119M 24.13%
3,905,000
-50,000
-1% -$1.34M
2018 Q3
27 quarters
ETON icon
2
Eton Pharmaceutcials
ETON
$1.58B
$40.8M 8.25%
2,860,000
+7,930
+0.3% +$125K
2018 Q4
26 quarters
IMNM icon
3
Immunome
IMNM
$2.26B
$32.8M 6.64%
3,529,581
-20,419
-0.6% -$167K
2024 Q2
4 quarters
SNWV icon
4
SANUWAVE Health Inc
SNWV
$50.2M
$32.2M 6.52%
980,000
+7,998
+0.8% +$242K
2025 Q1
1 quarter
LQDA icon
5
Liquidia Corp
LQDA
$2.48B
$30.8M 6.24%
2,475,000
+215,000
+10% +$3.18M
2021 Q4
14 quarters
CDXS icon
6
Codexis
CDXS
$154M
$30.7M 6.22%
12,600,000
+3,100,000
+33% +$7.27M
2014 Q1
45 quarters
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$6.18B
$30M 6.07%
475,000
-15,000
-3% -$918K
2022 Q2
12 quarters
TGTX icon
8
TG Therapeutics
TGTX
$8.46B
$19.3M 3.9%
535,000
– –
2023 Q3
7 quarters
OCUL icon
9
Ocular Therapeutix
OCUL
$1.66B
$14.8M 3%
1,595,000
– –
2019 Q1
25 quarters
ARVN icon
10
Arvinas
ARVN
$487M
$12.4M 2.5%
1,680,000
-295,000
-15% -$2.17M
2023 Q4
6 quarters
LRMR icon
11
Larimar Therapeutics
LRMR
$263M
$11.9M 2.4%
4,110,000
+2,195,923
+115% +$5.08M
2025 Q1
1 quarter
IRON icon
12
Disc Medicine
IRON
$2.32B
$9.87M 2%
186,418
+101,418
+119% +$4.76M
2025 Q1
1 quarter
SRPT icon
13
Sarepta Therapeutics
SRPT
$1.84B
$8.55M 1.73%
+500,000
New +$21.3M
2025 Q2
0 quarters
VIGL icon
14
DELISTED
Vigil Neuroscience
VIGL
$7.95M 1.61%
+1,000,000
New +$4.48M
2025 Q2
0 quarters
CGON icon
15
CG Oncology
CGON
$5.6B
$6.92M 1.4%
266,000
+102,012
+62% +$2.46M
2025 Q1
1 quarter
XOMA icon
16
DELISTED
Xoma
XOMA
$6.43M 1.3%
255,087
+2,044
+0.8% +$49K
2017 Q1
33 quarters
EWTX icon
17
Edgewise Therapeutics
EWTX
$4.18B
$6.42M 1.3%
490,000
+95,000
+24% +$1.37M
2022 Q1
13 quarters
STOK icon
18
Stoke Therapeutics
STOK
$1.56B
$6.38M 1.29%
562,120
+262,120
+87% +$2.49M
2024 Q4
2 quarters
ANIK icon
19
Anika Therapeutics
ANIK
$274M
$6.23M 1.26%
588,797
+193,797
+49% +$2.45M
2025 Q1
1 quarter
PTGX icon
20
Protagonist Therapeutics
PTGX
$9.37B
$5.8M 1.17%
105,000
– –
2023 Q4
6 quarters
DNA icon
21
Ginkgo Bioworks
DNA
$794M
$5.63M 1.14%
500,000
-695,000
-58% -$5.38M
2024 Q3
3 quarters
GOSS icon
22
Gossamer Bio
GOSS
$56.8M
$4.36M 0.88%
44,313
-9,280
-17% -$810K
2023 Q2
8 quarters
RZLT icon
23
Rezolute
RZLT
$471M
$4.03M 0.82%
903,442
+438,442
+94% +$1.63M
2024 Q3
3 quarters
RVMD icon
24
Revolution Medicines
RVMD
$41.6B
$3.86M 0.78%
+105,000
New +$4.03M
2025 Q2
0 quarters
EPIX icon
25
DELISTED
ESSA Pharma
EPIX
$3.76M 0.76%
2,209,998
– –
2024 Q4
2 quarters
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2025 Portfolio in Review

As of Q2 2025, Opaleye Management held 50 positions worth $494M, up 10% from $449M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Opaleye Management deployed $16.8M of net new capital in Q2 2025, opening 5 new positions and adding to 15 existing holdings. Its largest new stake was Sarepta Therapeutics: 500,000 shares worth $8.55M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ginkgo Bioworks, an estimated $5.38M trimmed.

  • Opaleye Management's largest Q2 2025 buy was Sarepta Therapeutics: 500,000 shares worth $8.55M.
  • Opaleye Management added most to Codexis in Q2 2025, an estimated $7.27M increase.
  • Opaleye Management's biggest Q2 2025 reduction was Ginkgo Bioworks, cutting an estimated $5.38M.
  • Opaleye Management fully exited Palvella Therapeutics in Q2 2025, selling an estimated $4.82M.
  • Opaleye Management's ten largest holdings make up 73% of its $494M portfolio in Q2 2025.
  • Opaleye Management opened 5 new positions and closed 9 in Q2 2025.
  • Opaleye Management's portfolio value rose 10% quarter-over-quarter to $494M.

Based on Opaleye Management's 13F filing for Q2 2025, filed 14 Aug 2025.